Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05871918
Other study ID # CIH-TZS-20201008-01
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 8, 2022
Est. completion date December 31, 2023

Study information

Verified date October 2022
Source Tianjin Medical University Cancer Institute and Hospital
Contact Zhongsheng Tong
Phone +8618622221181
Email 18622221181@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is being conducted to assess the efficacy and safety of anthracycline-containing ddEC-THP intensive regimen and an anthracycline-free TCbHP neoadjuvant therapy for HER2-positive breast cancer


Description:

A Multicenter, Randomized, Open, Phase III,The study is being conducted to assess the efficacy and safety of anthracycline-containing ddEC-THP intensive regimen and an anthracycline-free TCbHP neoadjuvant therapy for HER2-positive breast cancer,Subjects will be treated until disease progression, toxicity is intolerable, informed consent is withdrawn, and investigators determine that medication must be discontinued. Drug efficacy and safety data will be collected.


Recruitment information / eligibility

Status Recruiting
Enrollment 832
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age: 18 ~70 years old, female; 2. Histologically confirmed patients with previously untreated stage ?-? HER2-positive breast cancer; 3. HER-2 positive breast cancer, defined as immunohistochemical (IHC) detection of 3+ or in situ hybridization (FISH) results of HER2 gene amplification; 4. There is at least one measurable objective lesion according to RECIST 1.1 criteria; 5. ECOG Physical fitness score is 0-2; 6. Left ventricular ejection fraction LVEF=50%; 7. Bone marrow function: neutrophils =1.5×109/L, platelets =100×109/L, hemoglobin =90g/L; 8. Liver and kidney function: serum creatinine =1.5 times the upper limit of normal value; AST and ALT=2.5 times the upper limit of normal, or =5 times the upper limit of normal in the presence of liver metastasis; Total bilirubin =1.5 times the upper limit of normal, or =2.5 times the upper limit of normal in patients with Gilbert's syndrome, creatinine clearance greater than 30 mL/min; 9. For female patients who are not menopausal or have not been surgically sterilized: consent to abstinence or use an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment 10. The patient has good compliance with the planned treatment, can understand the research process of the study and sign the written informed consent. Exclusion Criteria: 1. Stage IV (metastatic) breast cancer patients; 2. Patients with inflammatory breast cancer 3. Serious heart disease or discomfort, including but not limited to: - History of heart failure or systolic dysfunction (LVEF < 50%) - High-risk uncontrolled arrhythmias such as atrial tachycardia, resting heart rate > 100 bpm, significant ventricular arrhythmias (e.g., ventricular tachycardia) or higher-grade atrioventricular block (i.e., Mobitz II second-degree atrioventricular block or third-degree atrioventricular block) Angina pectoris that requires antiangina medication - valvular heart disease of clinical significance - ECG showed transmural myocardial infarction - Poor hypertension control (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg) 4. Known allergic history of drug components of this protocol; A history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation; 5. Patients with severe systemic infection or accompanied by other serious diseases; 6. Have developed other malignant tumors within the previous 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer; 7. Pregnant and lactating women, fertile women who tested positive for baseline pregnancy tests, or patients of childbearing age who were unwilling to take effective contraceptive measures during the entire trial period and within 6 months after the last study; 8. Patients who participated in other studies within 30 days prior to the first dose of the investigational drug; 9. Patients deemed unsuitable for this study by the investigator. 10. The patient has good compliance with the planned treatment, can understand the research process of the study and sign the written informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TCbHP VS ddEC-THP
The efficacy was evaluated every two cycles, and the effective patients (CR, PR, SD) were treated with surgery after 6 cycles. If treatment does not work, change the treatment plan according to the clinician's decision.

Locations

Country Name City State
China Breast Oncology, Tianjin Medical University Cancer Institute and Hospital Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary pCR rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery pCR rate (ypT0/is,ypN0) is defined as the percentage of participants without residual invasive tumor on hematoxylin and eosin evaluation of breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy by current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery in all participants. Up to approximately 24 weeks
Secondary Event-Free Survival (EFS) EFS is defined as the time from start of study treatment to any of the following events: progression of disease that precludes surgery, local or distant recurrence, second primary malignancy (breast or other cancers) or death due to any cause. Up to approximately 3 years
Secondary Invasive Disease-Free Survival (iDFS) iDFS events are defined as follows: (1)Ipsilateral invasive breast tumor recurrence. (2) Ipsilateral local-regional invasive breast cancer recurrence. (3) Ipsilateral second primary invasive breast cancer. (4) Contralateral invasive breast cancer. (5) Distant recurrence. (6) Death attributable to any cause. Up to approximately 3 years
Secondary Overall survival (OS) OS is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis will be censored at the date of the last follow-up. Up to approximately 3 years
See also
  Status Clinical Trial Phase
Completed NCT01305941 - A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Phase 2
Completed NCT01432223 - Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab Phase 2
Completed NCT01433926 - Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than 3 Years N/A
Terminated NCT02598310 - Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer Phase 2
Active, not recruiting NCT02568839 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer Phase 2/Phase 3
Completed NCT02675231 - A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer Phase 2
Terminated NCT02154529 - Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT01565200 - HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 Phase 2
Completed NCT01340430 - Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer Phase 2
Active, not recruiting NCT02947685 - Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Phase 3
Completed NCT02066532 - Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Phase 1/Phase 2
Completed NCT01677455 - An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer Phase 2
Completed NCT01583426 - Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Phase 3
Withdrawn NCT01361945 - AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer Phase 1/Phase 2
Active, not recruiting NCT02326974 - T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA Phase 2
Not yet recruiting NCT04644406 - PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
Terminated NCT02131506 - A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer Phase 1
Completed NCT00788931 - A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer Phase 1
Completed NCT02488564 - A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer Phase 2
Completed NCT02492711 - Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Phase 3